THIS SERVICE IS NOT AVAILABLE IN YOUR REGION

ABT

Canada

Founded in

2018 (8 Years)

Founded

Last online: No recent activity

Visit website

TrustScore unavailableNot enough score to display the trend.

Be the first to rate and review this company.

OVERALL SCORE

Licenses

--/40

Reviews

--/60

0 reviews

Provided by TrustFinance

TrustScore unavailableNot enough score to display the trend.

Be the first to rate and review this company.

Regulated

Recommended

XM

(67 reviews)

Cyprus

2009

(17 years)

Security Information :

CySEC

FSCA

DFSA

Security Information

Warning

This company is currently Unproved.

Please be cautious of the potential risks!

License

A Grade License

Issued by globally renowned regulators, these licenses ensure the highest trader protection through strict compliance, fund segregation, insurance, and regular audits. Dispute resolution and adherence to AML/CTF standards further enhance security.

B Grade License

Granted by respected regional regulators, these licenses offer robust safety measures such as fund segregation, financial reporting, and compensation schemes. Though slightly less strict than Tier 1, they provide dependable regional protection.

C Grade License

Issued by regulators in emerging markets, these licenses offer basic protections such as minimum capital requirements and AML policies. Oversight is less stringent, so traders should exercise caution and verify safety measures.

D Grade License

From jurisdictions with minimal oversight, these licenses often lack key protections like fund segregation and insurance. While attractive for operational flexibility, they pose higher risks to traders.

Reviews

ABT Reviews

Reviews

Total 0

Sort by

Filter

Company Information

Get to know ABT

ABT GROUP LTD, operating under the brand name ABT, is a financial services provider that offers online trading through the MetaTrader 5 (MT5) platform. The company provides access to leveraged trading on a variety of asset classes, including foreign exchange, global indices, precious metals, energies, and cryptocurrencies. Registered in the offshore jurisdiction of St. Vincent and the Grenadines, the firm targets a global retail trading audience.

Industry

Forex Retail BrokerPRIMARY
Crypto Cryptocurrency
Financial Financial Advisement

Software

No data available

Looks like this section is empty. Come back soon for updates!

Contact

Social

News

TrustFinance Intelligence Agency

Research date: Apr 28, 2026

The website indicates that the training data is current only up to October 2023.

The content discusses Abbott Laboratories' stock performance and future predictions. Analysts predict a potential decline in stock value due to challenges in the nutrition and diagnostics divisions, despite a strong performance in the medical devices segment. The stock is currently trading around $124 with a market cap of $216.57 billion and a consensus buy rating with a target price of $143. Factors affecting the stock include competition from Medtronic and Boston Scientific, as well as declining COVID-19 test sales. Investment considerations highlight Abbott's strengths and challenges in maintaining growth in a competitive market.

The content discusses Abbott Laboratories' stock performance and future predictions. Analysts predict a potential decline in stock value due to challenges in the nutrition and diagnostics divisions, despite a strong performance in the medical devices segment. The stock is currently trading around $124 with a market cap of $216.57 billion and a consensus buy rating with a target price of $143. Factors affecting the stock include competition from Medtronic and Boston Scientific, as well as declining COVID-19 test sales. Investment considerations highlight Abbott's strengths and challenges in maintaining growth in a competitive market.

The article discusses Abbott Laboratories (ticker: ABT), highlighting a consensus rating of 'buy' from 21 analysts, with a target price of $124.04, indicating an 8.4% upside potential from its current price of $113.10. The company operates in various segments including pharmaceuticals, diagnostics, nutrition, and medical devices, with a market cap of $196.78 billion and a P/E ratio of 35.68. The report provides additional financial metrics and insights into the company's product offerings.

The article discusses Abbott Laboratories (ticker: ABT), highlighting a consensus rating of 'buy' from 21 analysts, with a target price of $124.04, indicating an 8.4% upside potential from its current price of $113.10. The company operates in various segments including pharmaceuticals, diagnostics, nutrition, and medical devices, with a market cap of $196.78 billion and a P/E ratio of 35.68. The report provides additional financial metrics and insights into the company's product offerings.

The Better Business Bureau warns about a rise in scams involving fake classic car and heavy equipment websites, tricking consumers into losing large sums of money. Recent examples include victims losing $25,000, $36,000, and $27,000 to scammers posing as legitimate dealerships. The BBB advises consumers to inspect vehicles in person, be cautious of deals that seem too good to be true, and use approved VIN lookup websites to verify vehicle history.

The Better Business Bureau warns about a rise in scams involving fake classic car and heavy equipment websites, tricking consumers into losing large sums of money. Recent examples include victims losing $25,000, $36,000, and $27,000 to scammers posing as legitimate dealerships. The BBB advises consumers to inspect vehicles in person, be cautious of deals that seem too good to be true, and use approved VIN lookup websites to verify vehicle history.

The website provides a comprehensive suite of research tools and resources for investors, including stock screeners, calculators, trending stocks, premium reports, financial calendars, and analyst ratings. It features detailed information on various stocks, including Abbott Laboratories, with insights into their market performance, earnings, dividends, and insider trading. The content is designed to assist users in making informed investment decisions and includes educational resources on financial terms and investment strategies.

The website provides a comprehensive suite of research tools and resources for investors, including stock screeners, calculators, trending stocks, premium reports, financial calendars, and analyst ratings. It features detailed information on various stocks, including Abbott Laboratories, with insights into their market performance, earnings, dividends, and insider trading. The content is designed to assist users in making informed investment decisions and includes educational resources on financial terms and investment strategies.

Provided by TrustFinance AI Analysis

News

TrustFinance Intelligence Agency

Research date: Apr 28, 2026

The website indicates that the training data is current only up to October 2023.

The content discusses Abbott Laboratories' stock performance and future predictions. Analysts predict a potential decline in stock value due to challenges in the nutrition and diagnostics divisions, despite a strong performance in the medical devices segment. The stock is currently trading around $124 with a market cap of $216.57 billion and a consensus buy rating with a target price of $143. Factors affecting the stock include competition from Medtronic and Boston Scientific, as well as declining COVID-19 test sales. Investment considerations highlight Abbott's strengths and challenges in maintaining growth in a competitive market.

The article discusses Abbott Laboratories (ticker: ABT), highlighting a consensus rating of 'buy' from 21 analysts, with a target price of $124.04, indicating an 8.4% upside potential from its current price of $113.10. The company operates in various segments including pharmaceuticals, diagnostics, nutrition, and medical devices, with a market cap of $196.78 billion and a P/E ratio of 35.68. The report provides additional financial metrics and insights into the company's product offerings.

The Better Business Bureau warns about a rise in scams involving fake classic car and heavy equipment websites, tricking consumers into losing large sums of money. Recent examples include victims losing $25,000, $36,000, and $27,000 to scammers posing as legitimate dealerships. The BBB advises consumers to inspect vehicles in person, be cautious of deals that seem too good to be true, and use approved VIN lookup websites to verify vehicle history.

The website provides a comprehensive suite of research tools and resources for investors, including stock screeners, calculators, trending stocks, premium reports, financial calendars, and analyst ratings. It features detailed information on various stocks, including Abbott Laboratories, with insights into their market performance, earnings, dividends, and insider trading. The content is designed to assist users in making informed investment decisions and includes educational resources on financial terms and investment strategies.

Provided by TrustFinance AI Analysis

ABT

XM

Company Information

Company Information